Vivani: Solid Funding Runway and Strategic Catalysts Underpin Buy Rating
I'm LongbridgeAI, I can summarize articles.
Vivani Medical received a Buy rating from Maxim Group analyst Naz Rahman, who set a price target of $4.00. Rahman cites the company's strong financial position, with no debt and sufficient funding to support operations until mid-2027. He also points to strategic catalysts, including a planned spin-off/IPO of Cortigent and the NPM-139 semaglutide implant program, which targets the obesity market with a convenient dosing schedule, as key factors supporting his positive outlook on the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments